Objective To evaluate the efficacy and safety of adalimumab (ADA) in the treatment of moderate to severe Crohn's disease (CD),and to explore the efficacy of switching to ADA as second-line treatment after failure of infliximab (IFX). Methods The clinical data of 80 patients with moderate to severe CD diagnosed from January 2019 to December 2022 were retrospectively analyzed. They were randomly divided into the control group and the observation group,with 40 cases in each group. The improvement of disease activity and overall adverse events were compared between the two groups at 12,26,and 52 weeks of treatment,and the differences in efficacy between the first-line treatment group and the second-line treatment group after IFX treatment failure were evaluated at 4,12,26,and 52 weeks. Results There were significant differences in clinical response rate at 12,26,52 weeks and remission rate at 12 weeks between the two groups (P<0.05). The scores of inflammatory bowel disease questionnaire (IBD-Q) in the observation group at 4,12,26 and 52 weeks were significantly different from those before treatment (P<0.05). There were no significant differences in C-reactive protein (CRP),erythrocyte sedimentation rate (ESR),Crohn's disease activity index (CDIA),IBD-Q,clinical response rate,clinical remission rate,endoscopic response rate,endoscopic remission rate and mucosal healing rate between 21 patients with first-line ADA treatment and 19 patients with ADA who failed IFX treatment as second-line treatment (P>0.05). Conclusion ADA monoclonal antibody is effective in the treatment of moderate to severe CD patients,and ADA can also be recommended as a second-line biological agent for IFX.
Crohn's diseaseAdalimumabEfficacySafetyQuality of life
万方数据
维普
